Premium
Effect of CYP2D6, CYP3A5, and MDR1 Genetic Polymorphisms on the Pharmacokinetics of Risperidone and Its Active Moiety
Author(s) -
Xiang Qian,
Zhao Xia,
Zhou Ying,
Duan Jing Li,
Cui Yi Min
Publication year - 2010
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270009347867
Subject(s) - risperidone , cyp2d6 , pharmacokinetics , pharmacology , active metabolite , cyp3a5 , medicine , genotype , pharmacogenetics , schizophrenia (object oriented programming) , biology , genetics , psychiatry , cytochrome p450 , metabolism , gene
Clinical studies suggest that plasma levels of risperidone and its active moiety (risperidone + 9‐hydroxyrisperidone) correlate with adverse drug effects. The aim of this study is to evaluate the pharmacogenetic variability in the disposition of risperidone and the active moiety in healthy Chinese subjects. A 2‐mg single dose of risperidone is orally administered to 23 healthy Chinese subjects. The risperidone and 9‐hydroxyrisperidone serum concentrations are measured. The polymorphic alleles of CYP2D6*10, CYP3A5*3, MDR1 C1236T, G2677T/A, and C3435T are determined in each subject. The mean maximum plasma concentration and area under the time‐concentration curve extrapolated to infinity for risperidone are significantly higher in subjects possessing the CYP2D6*10 allele than in those with the CYP2D6*1/*1 and *1/*10 genotype. For active moiety, the subjects who carry both homozygous CYP2D6*10 and homozygous CYP3A5*3 have 98% higher area under the time‐concentration curve extrapolated to infinity and 59% higher maximum plasma concentration compared with other CYP2D6 EM subjects. The MDR1 2677GA genotype may also play a role in risperidone pharmacokinetics. Further studies are needed to explore the impact of MDR1 2677GA and CYP3A5 polymorphisms on risperidone therapy.